No retraction, correction or concern found when last checked on Oct 16, 2026.

APP processing in Alzheimer's disease

Yun-wu Zhang, Robert Thompson, Han Zhang and 1 more

Molecular Brain · 2011 · Review

Abstract

An important pathological feature of Alzheimer's disease (AD) is the presence of extracellular senile plaques in the brain. Senile plaques are composed of aggregations of small peptides called β-amyloid (Aβ). Multiple lines of evidence demonstrate that overproduction/aggregation of Aβ in the brain is a primary cause of AD and inhibition of Aβ generation has become a hot topic in AD research. Aβ is generated from β-amyloid precursor protein (APP) through sequential cleavages first by β-secretase and then by γ-secretase complex. Alternatively, APP can be cleaved by α-secretase within the Aβ domain to release soluble APPα and preclude Aβ generation. Cleavage of APP by caspases may also contribute to AD pathologies. Therefore, understanding the metabolism/processing of APP is crucial for AD therapeutics. Here we review current knowledge of APP processing regulation as well as the patho/physiological functions of APP and its metabolites.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Background

1Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, afflicting 10% of the population over the age of 65 and 50% of the population over the age of 85. A small subset (<10%) of AD cases result from an inherited autosomal dominant gene mutation and have an early-onset (the fourth to sixth decade). The majority of these familial AD (FAD) mutations are in the genes encoding β-amyloid precursor protein (APP) and presenilins (PS1 and PS2). Significant efforts have gone into understanding the mechanisms underlying the genes tied to FAD as the clinicopathological features are indistinguishable from regular onset AD.

2AD is characterized in patients by an inexorably progressing dementia. In vulnerable brain regions, such as the hippocampus and cortex, there is an accumulation of extracellular neuritic plaques and intracellular neurofibrillary tangles. The neurofibrillary tangles (NFTs) consist largely of hyperphosphorylated twisted filaments of the microtubule-associated protein tau. Extracellular neuritic plaques are deposits of differently sized small peptides called β-amyloid (Aβ) that are derived via sequential proteolytic cleavages of the β-amyloid precursor protein (APP).

APP and Its Function

3The APP gene is located on chromosome 21 in humans with three major isoforms arising from alternative splicing. These are APP695, APP751 and APP770 (containing 695, 751, and 770 amino acids, respectively). APP751 and APP770 are expressed in most tissues and contain a 56 amino acid Kunitz Protease Inhibitor (KPI) domain within their extracellular regions. APP695 is predominantly expressed in neurons and lacks the KPI domain. There are reports showing that the protein and mRNA levels of KPI-containing APP isoforms are elevated in AD brain and associated with increased Aβ deposition; and prolonged activation of extrasynaptic NMDA receptor in neurons can shift APP expression from APP695 to KPI-containing APP isoforms, accompanied with increased production of Aβ. These findings may suggest that a dysregulated splicing of APP RNA contributes to disease pathogenesis.

4APP belongs to a protein family that includes APP-like protein 1 (APLP1) and 2 (APLP2) in mammals, all are type-I transmembrane proteins and are processed in a similar fashion. The Aβ domain is unique to the APP protein, though the family shares several other conserved domains such as the E1 and E2 domains in the extracellular sequence. Studies with APP knockout mice suggest some functional redundancy between these APP homologs that appears to be exerted by motifs other than Aβ. APP knockout mice are viable and fertile, showing a relatively subtle abnormal phenotype. APLP1 and APLP2 knockout mice are also viable and fertile, though APP/APLP2 and APLP1/APLP2 double null mice and APP/APLP1/APLP2 triple null mice show early postnatal lethality. Interestingly, the APP/APLP1 double null mice are viable, suggesting that APLP2 is crucial when either APP or APLP1 is absent.

5Although APP has been the subject of much study since its identification, its physiological function remains largely undetermined. A role for APP has been suggested in neurite outgrowth and synaptogenesis, neuronal protein trafficking along the axon, transmembrane signal transduction, cell adhesion, calcium metabolism, etc, all requiring additional in vivo evidence (reviewed in). APP is proteolyzed into various fragments (see Figure 1) during its intracellular trafficking and these APP metabolites mediate various and sometimes adverse functions. Therefore, the net effect of full-length APP on cellular activity may be a combination of its metabolites' functions, temporospatially depending on the proportion of levels of each APP metabolite. Here we list several possible functions of full-length APP per se.

6The similarity in topology and proteolytic processing between APP and Notch suggest that APP may function as a membrane receptor like Notch. Indeed, several APP ligands have been identified, such as Aβ, F-spondin and nectrin-1. However, while binding of APP by these ligands can affect APP processing, the exact downstream signaling events triggered by such binding remains to be clarified and a bona fide membrane receptor function for APP remains speculative.

7There is evidence linking APP to cell adhesion. APP was found to colocalize with β1 intergrins in neural cells. An X-ray analysis showed that the E2 domain of APP can form antiparallel dimers. Indeed, further study in cell cultures demonstrated that APP can form homodimers and heterodimers in a trans-dimerization manner with other APP family members and that such dimerization promotes intercellular adhesion.

8APP undergoes rapid anterograde transport in neurons. During its transport, APP was found to interact with kinesin-I and functions as a kinesin-I membrane receptor to mediate axonal transport of β-secretase (BACE1) and PS1. However, another study failed to verify the interaction between APP and kinesin-I and the co-transport of BACE1 and PS1 with APP. We recently found that APP and its derived membrane-associated form, CTFs, can regulate cell surface delivery of PS1/γ-secretase but not BACE1. In addition, APP was found to be a major component of herpes simplex viral particles and likely mediates fast anterograde transport of these particles. Another study showed that increased doses of APP markedly decreased retrograde transport of nerve growth factor and resulted in degeneration of forebrain cholinergic neurons in a mouse model of Down's Syndrome. APP was also found to interact with high-affinity choline transporter (CHT) through the C-terminal domain and APP deficiency affected CHT endocytosis. Overall, most studies suggest that APP plays some role in regulating protein trafficking.

APP Processing

9Full-length APP is a type I transmembrane protein. APP is synthesized in the endoplasmic reticulum (ER) and then transported through the Golgi apparatus to the trans-Golgi-network (TGN) where the highest concentration of APP is found in neurons at steady state. Aβ is generated in the ER and Golgi/TGN. From the TGN, APP can be transported in TGN-derived secretory vesicles to the cell surface where it is either cleaved by α-secretase to produce a soluble molecule, sAPPα, or re-internalized via an endosomal/lysosomal degradation pathway. It has been proposed that Aβ can also be generated in the endosomal/lysosomal system. While Aβ is neurotoxic, studies suggest that sAPPα is neuroprotective, making the subcellular distribution of APP an important factor in neurodegeneration. Delineation of the mechanisms involved in APP trafficking are thus relevant and crucial to understanding the pathogenesis of AD.

α-secretase and α-processing

10Cleavage of APP by α-secretase precludes Aβ generation as the cleavage site is within the Aβ domain (at the Lys16-Leu17 bond), and releases a large soluble ectodomain of APP called sAPPα. The generation of sAPPα is a constitutive event but can also be regulated by various reagents. Early studies suggested that α-secretase is a membrane-bound endoprotease which cleaves APP primarily at the plasma membrane. Using proteinase inhibitor profiling, it was determined that α-secretase is a zinc metalloproteinase. Several members of the ADAM (a disintegrin and metalloproteinase) family possess α-secretase-like activity and three of them have been suggested as the α-secretase: ADAM9, ADAM10, and ADAM17. Like APP, they are also type-I transmembrane proteins.

11ADAM17 (also called tumor necrosis factor-α converting enzyme, TACE) can be proteolytically cleaved to release its extracellular domain as soluble TGF-α. Manipulation of ADAM17 can alter α-cleavage of APP and Aβ generation, with regulated α-cleavage abolished in ADAM17-deficient cells, suggesting that ADAM17 is likely the α-secretase responsible for regulated APP cleavage. Additionally, an ADAM17 inhibitor prevented regulated α-secretase activity in human neurons, whereas RNAi downregulation of ADAM10 had no effect on α-cleavage of APP. Various other studies confirm that ADAM17 likely affects regulated, but not constitutive, α-cleavage in various cell lines.

12Co-expression of ADAM9 with APP promoted sAPPα production upon phorbol ester treatment, suggesting that ADAM9 possesses α-secretase activity. However, RNAi of ADAM9 had no effect on sAPPα generation, implying that ADAM9 is involved only in regulated α-cleavage.

13Overexpression of ADAM10 increases α-cleavage, whereas a dominant-negative form of ADAM10 and RNAi of ADAM10 inhibit endogenous α-cleavage activity in several cell lines, including murine primary neurons. Significantly, sAPPα generation was nearly abolished in the neurons of mice with neural ADAM10 conditionally knocked-out. A dramatically reduced ADAM10 protein level in the platelets of sporadic AD patients was also found to correlate with the significantly decreased sAPPα levels found in their platlets and cerebrospinal fluid and the reduced α-secretase activity in the temporal cortex homogenates of AD patients. These studies strongly suggest that ADAM10 is the constitutive α-secretase that is active at the cell surface, though there may be some functional redundancy in α-cleavage among the ADAM family.

14In contrast to Aβ, sAPPα has an important role in neuronal plasticity/survival and is protective against excitotoxicity. sAPPα also regulates neural stem cell proliferation and is important for early CNS development. We and others have also found that sAPPα can inhibit stress-induced CDK5 activation and participate in various neuroprotective reagent-mediated excitoprotection. Interestingly, expression of sAPPα alone is able to rescue the abnormalities of APP deficient mice, implying that most of APP's physiological function is mediated by sAPPα.

β-secretase and β-processing

15The first step in Aβ generation is cleavage of APP by the β-secretase. In 1999-2000, several groups concomitantly identified BACE1 (also called Asp2 or memapsin 2) as the major β-secretase. BACE1, the most common name for the protease, is a membrane-bound aspartyl protease with a characteristic type I transmembrane domain near the C-terminus. Overexpression or downregulation of BACE1 induces or inhibits cleavage of APP at the known β-site locations, Asp1 and Glu11, respectively. In vitro studies with synthetic APP peptides confirm cleavage by BACE1. These results provide convincing evidence that BACE1 is the β-secretase involved in APP metabolism; and BACE1 activity is thought to be the rate-limiting factor in Aβ generation from APP.

16A larger precursor, pro-BACE1, is modified by glycosylation, phosphorylation and cleaved by a furin-like endoprotease to produce mature BACE1. BACE1 requires an acidic environment for optimal activity and, as expected, overexpressed BACE1 in various pre-mitotic cell lines is mainly found in the early Golgi, late Golgi/early endosomes, and endosomes that provide an acidic environment. In addition, BACE1 can be found at the cell surface. The mechanisms regulating BACE1 trafficking and activity have not been fully elucidated. Some studies found that BACE1 can interact with reticulon/Nogo proteins, whose increased expression can block BACE1 in the ER with a neutral pH environment and thus inhibit BACE1 activity in Aβ generation. On the other hand, Golgi-localized γ-ear-containing ARF-binding (GGA) proteins have been found to interact with BACE1 and regulate its trafficking between the late Golgi and early endosomes; and depletion of GGA proteins increases the accumulation of BACE1 in acidic early endosomes for enhanced BACE1 stability and cleavage of APP.

17The viability of BACE1 as a therapeutic target has been investigated by a number of studies. An early study suggested that BACE1 knockout mice do not produce detectable levels of Aβ and have no severe phenotypic abnormalities. BACE1 deficiency in AD model mice have been shown to rescue cholinergic dysfunction, neuronal loss and memory deficits, correlating with a dramatic reduction in Aβ40/42 levels. Several studies have found that BACE1 protein and activity levels are elevated in the regions of the brain affected by AD. Together these results suggest BACE1 as a good therapeutic target for AD. However, more recent studies have found several phenotypic abnormalities in BACE1 KO mice. Dominguez et al. observed a variable but significant number of BACE1 null mice died in the first weeks after birth. The BACE1 null mice that survive were smaller than their littermates, presented with hyperactive behavior, and had subtle electrophysiological alterations in the steady-state inactivation of their voltage-gated sodium channels. They also were affected by hypomyelination of peripheral nerves and had altered neurological behaviors such as reduced grip strength and elevated pain sensitivity, likely due to the deficiency of neuregulin processing in the absence of BACE1, as neuregulin 1 is another substrate of BACE1. Furthermore, additional BACE1 substrates have been identified, including the voltage-gated sodium channel (Nav1) β2 subunit, Golgi-localized membrane-bound α2,6-sialyltransferase, P-selectin glycoprotein ligand -1, etc. (reviewed in). Therefore, BACE1 is likely not as safe a drug target as first assumed.

18BACE2 is a homolog of BACE1 that maps to 21q22.3, the region critical for Down's syndrome (DS). As DS also results in Aβ accumulation, the genes location suggests a link between BACE2 and APP processing. Indeed, BACE2 cleaves β-secretase substrates such as wild-type and Swedish mutant APP, similar to BACE1, in enzymatic In vitro assays. However, BACE2 expression in neurons is substantially lower than BACE1 and cellular BACE2 cleaves APP near the α-secretase site much more efficiently than at the β-secretase site. These results suggest that BACE1 is the primary β-secretase but do not exclude a potential contribution of BACE2 towards AD pathogenesis. While BACE2 knockout mice are healthy overall, a deficiency of both BACE1 and BACE2 enhanced the BACE1 KO lethality phenotype, suggesting a slight functional redundancy.

19In addition to BACE1 and BACE2, cathepsin B has been proposed as an additional β-secretase. Inhibition of cathepsin B has been found to reduce Aβ production both in vivo and in vitro. However, whether cathepsin B really exerts physiological β-secretase activity requires further validation.

20Upon β-cleavage, the ectodomain of APP is also released as soluble APPβ (sAPPβ). Although sAPPβ only differs from sAPPα by lacking the Aβ1-16 region at its carboxyl-terminus, sAPPβ was reported to function as a death receptor 6 ligand and mediate axonal pruning and neuronal cell death. A recent report found that sAPPβ can rescue gene expression of transthyretin and Klotho, which is decreased in APP/APLP2 deficient mice, but cannot rescue the lethality and neuromuscular synapse defects of these mice, suggesting a gene expression regulation function for sAPPβ that is independent of developmental APP functions.

21After α- and β-cleavage, the carboxyl terminal fragments (CTFs) of APP, known as αCTF and βCTF, respectively, remain membrane-associated and will be further cleaved by γ-secretase. Since these APP CTFs are intermediate products, their functions have been less characterized. However, overexpression of APP βCTF was found to be cytotoxic and cause neuronal degeneration, perhaps by perturbing APP signal transduction. It is also possible that APP βCTF's cytotoxic effect is actually mediated by the end products of γ- and/or caspase-cleavage including APP intracellular domain (AICD), C31 and Jcasp which are cytotoxic (see below). We recently found that APP βCTF can regulate cell surface delivery of γ-sceretase, perhaps through the direct binding of enzyme-substrate. It is possible that APP αCTF possesses a similar effect since it is also the substrate of γ-secretase.

γ-secretase and γ-processing

22APP αCTF and βCTF are further cleaved by γ-secretase to generate p83 and Aβ, respectively. The p83 fragment is rapidly degraded and widely believed to possess no important function, if any. γ-secretase-mediated cleavage is unique in that the cleavage takes place within the transmembrane domain, though the exact site can vary. γ-cleavage can yield both Aβ40, the majority species, and Aβ42, the more amyloidogenic species, as well as release the intracellular domain of APP (AICD). Recent data has shown that PS/γ-secretase also mediates ζ-site cleavage (Aβ46) and ε-site cleavage (Aβ49), suggesting a sequential cleavage model where cleavage at the ε-site is followed by the ζ-site and γ-site.

23Multiple lines of biochemical evidence have shown γ-secretase activity to reside in a high molecular weight complex consisting of at least four components: presenilin (PS, PS1 or PS2), Nicastrin, anterior pharynx-defective-1 (APH-1), and presenilin enhancer-2 (PEN-2). In mammals there are two presenilin homologs, PS1 and PS2. Mutations in these two genes, particularly PS1, are causative in the majority of familial AD (FAD) cases. PSs are multi-transmembrane proteins with an unclear number of transmembrane domains. Nascent PSs undergo endroproteolytic cleavage with the resulting amino-terminal fragment (NTF) and carboxyl-terminal fragment (CTF) forming a functional PS heterodimer. PSs possess two highly conserved aspartate residues indispensable for γ-secretase activity. The PS1 NTF/CTF heterodimers are bound by transition-state analogue γ-secretase inhibitors, suggesting that PSs are the crucial catalytic components of γ-secretase. This notion has recently been confirmed by in vitro assays. Nicastrin, the first identified cofactor of PS, is a type I transmembrane glycoprotein that is considered the scaffolding protein within the γ-secretase complex. One study showed that the ectodomain of Nicastrin binds to APP and Notch and can recruit them into the γ-secretase complex, suggesting that Nicastrin may act as the γ-secretase receptor. Another two components, APH1 and PEN2, were identified through genetic screening of Caenorhabditis elegans. APH-1 interacts with Nicastrin to form a stable intermediate in an early assembly stage of the γ-secretase complex. PEN-2 regulates PS endoproteolysis. Each of these four γ-secretase components has been found necessary for the enzymatic activity of the complex with deficiency in any of them dramatically impairing γ-secretase activity. Coexpression of the four components in the yeast Saccharomyces cerevisiae has been found to be necessary and sufficient to reconstitute γ-secretase activity, which is not endogenous to yeast.

24In addition to the four critical components, several other factors have been proposed as additional γ-secretase components. However, these factors play a modulatory role and are not essential for γ-secretase activity: CD147 is a transmembrane glycoprotein and interacts with all four essential γ-secretase components. Downregulation of CD147 increases Aβ production but its overexpression has no effect on Aβ generation. TMP21/p23 binds to the γ-secretase complex and regulates γ-cleavage, but not ε-cleavage, through its transmembrane domain. However, another study failed to confirm the binding of TMP23/p21 to γ-secretase, but rather suggested that TMP21/p23, which belongs to the p24 cargo family involved in vesicular trafficking regulation, influences APP trafficking and thus Aβ generation. Recently, a novel γ-secretase activating protein (GSAP) was identified and GSAP was found to selectively increase Aβ production through interaction with both γ-secretase and the APP CTF substrate. Additional validation and investigation of the role of these proteins in the γ-secretase complex is required.

25Strong evidence suggests that the γ-secretase complex resides primarily in the ER, Golgi/TGN, endocytic and intermediate compartments--most of which (except the TGN) are not major subcellular localizations for APP. In addition to cleaving APP CTFs, γ-secretase cleaves a series of functionally important transmembrane proteins, including Notch, cadherin, tyrosinase, ErbB4, CD44, etc.) (see review). The cleavage of various substrates appears to be dependent on the subcellular compartment; APP is mainly cleaved in the TGN and early endosomal domains whereas Notch is primarily cleaved at the plasma membrane. Thus a disturbance in the localization of the γ-secretase complex may play some role in abnormal Aβ generation and AD pathogenesis.

26γ-cleavage can release the intracellular domains (ICDs) of the substrates. Notch intracellular domain (NICD) is well-known to translocate into the nucleus and regulate genes critical to development. The other intracellular domains may be of comparable importance. For example, the ErbB4 ICD has been found to bind to astrocytic gene promoters to suppress their expression. In a similar fashion, released AICD has been shown to possess transactivation activity and can regulate transcription of multiple genes including APP, GSK-3β, KAI1, neprilysin, BACE1, p53, EGFR, and LRP1. In addition, free AICD can induce apoptosis and may play a role in sensitizing neurons to toxic stimuli. However, as the intracellular domain of APP, one important function of AICD is to facilitate the interaction of APP with various cytosolic factors that regulate APP's intracellular trafficking and/or signal transduction function. Interestingly, it seems that AICD-mediated APP interaction with different factors is controlled by the phosphorylation state of AICD.

Caspase processing

27In addition to secretases, caspases (predominantly caspase-3) can directly cleave APP at position Asp664 (based on the APP695 sequence) within the cytoplasmic tail during apoptosis to release a fragment containing the last 31 amino acids of APP (called C31). Additional γ-cleavage further generates the fragment (called Jcasp) containing the region between γ- and caspase-cleavage sites. Although original data found that caspase cleavage affects amyloidogenic processing of APP, further study suggests not. However, during Aβ-induced neurotoxicity, activated caspases cleave APP to generate C31 and Jcasp, which are also neurotoxic, therefore initiating a detrimental cascade. One possible mechanism for C31's toxicity is that C31 complexes with APP to recruit the interacting partners that initiate the signals related to cellular toxicity. Compared to C31, Jcasp appears to play a minor role in cytotoxicity. Importantly, caspase cleavage of APP seems to be crucial for Aβ-mediated neurotoxicity, as an APP mutation at position Asp664 to inhibit the caspase-cleavage in transgenic mice negated the synapse, electrophysiology, and behavioral abnormalities, even though Aβ plaques were still abundant in the brain.

Aβ Function

28The neurotoxic effect of Aβ has been well-established and will not be specifically emphasized here. Multiple lines of evidence demonstrate that overproduction of Aβ results in a neurodegenerative cascade leading to synaptic dysfunction, formation of intraneuronal fibrillary tangles and eventually neuron loss in affected areas of the brain. There are two main toxic species, Aβ40 and Aβ42, with Aβ42 more hydrophobic and more prone to fibril formation while only making up about 10% of the Aβ peptide produced. Studies done on familial AD (FAD) mutations consistently show increases in the ratio of Aβ42/40, suggesting that elevated levels of Aβ42 relative to Aβ40 is critical for AD pathogenesis, probably by providing the core for Aβ assembly into oligomers, fibrils and amyloidogenic plaques.

29Although the majority of Aβ is secreted out of the cell, Aβ can be generated in several subcellular compartments within the cell, such as the ER, Golgi/TGN, and endosome/lysosome. In addition, extracellular Aβ can be internalized by the cell for degradation. The intracellular existence of Aβ implies that Aβ may accumulate within neurons and contribute to disease pathogenesis. Confirming this, intraneuronal Aβ immunoreactivity has been found in the hippocampal and entorhinal cortical regions which are prone to early AD pathology in patients with mild cognitive impairment (MCI). In Down Syndrome (DS) patients, the accumulation of intracellular Aβ precedes extracellular plaque formation and the level of intraneuronal Aβ decreases as the extracellular Aβ plaques accumulate. Studies with transgenic mouse models consistently confirm these results, revealing intracellular Aβ accumulation as an early event in the neuropathological phenotype with decreasing intraneuronal levels of Aβ as extracellular plaques build up. Intraneuronal Aβ can also impair amygdala-dependent emotional responses by affecting the ERK/MAPK signaling pathway. Inhibition of dynamin-mediated but not clathrin-mediated Aβ internalization was also found to reduce Aβ-induced neurotoxicity. One recent study suggests that internalized Aβ can aggregate within the cell and disrupt the vesicular membrane, thus contributing to its pathological effect.

30Aβ was originally regarded as an abnormal and toxic species restricted to the brains of aged or demented humans. The discovery of soluble Aβ species in the bodily fluids of various species and in the conditioned medium of cultured cells has refuted this concept and implied a physiological function for Aβ. Although excessive Aβ causes synaptic dysfunction and synapse loss, low levels of Aβ increase hippocampal long-term potentiation and enhances memory, indicating a novel positive, modulatory role on neurotransmission and memory. Picomolar levels of Aβ can also rescue neuronal cell death induced by inhibition of Aβ generation (by exposure to inhibitors of β- or γ-scretases), possibly through regulating the potassium ion channel expression, hence affecting neuronal excitability. One study using a transgenic Caenorpabditis elegans model found that intracellular Aβ aggregation in muscle cells may trap excess free copper to reduce copper-mediated cytotoxic effects. However, whether Aβ can form intracellular aggregates in human peripheral cells to exert a physiologically protective function remains to be determined.

Regulation of APP Processing at the Trafficking Level

31Alterations in APP intracellular trafficking and localization directly impact Aβ production as APP is processed by two mutually exclusive pathways. The available evidence has shown that intracellular trafficking of APP is regulated by a number of factors.

Trafficking factors

32Intracellular trafficking of proteins requires the involvement of a series of cytosolic factors. An increasing number of proteins that interact with APP or act as trafficking factors are being implicated in the regulation of Aβ generation and APP trafficking. For example, the APP C-terminus has been found to interact with all three mint (X11) family members (mint1, mint2, and mint3) involved in trafficking regulation. APP interaction with mint proteins has been shown to affect APP processing by stabilizing cellular APP, altering both sAPPα and Aβ generation and secretion. Rab6, a member of the GTP-binding protein family of membrane trafficking regulators, is implicated in protein transport along biosynthetic and endocytic pathways and has also been found to affect APP processing. Moreover, internalization of APP from the cell surface for endosomal/lysosomal degradation can be mediated by clathrin. Clathrin-modulated endocytosis is tightly controlled, requiring the participation of AP-2, dynamin I, and many other factors. When the endocytic pathway is inhibited by overexpression of a dominant-negative form of dynamin I, APP processing is also affected. It is conceivable that other important vesicular transport factors may also affect APP processing through regulation of general protein trafficking.

33In addition to general trafficking modulators, several other proteins have been found to regulate APP trafficking in a more specific manner, possibly through their direct binding to APP. PS1 is the catalytic component of the γ-secretase complex but has also been demonstrated to regulate the intracellular trafficking of several membrane proteins, including the other γ-secretase components (nicastrin, APH-1 and PEN-2), TrkB, and ICAM-5/telecephalin. We and others have shown that PS1 can also regulate the intracellular trafficking of APP. Expression of a loss of function PS1 variant, or the absence of PS1, results in increased budding/generation of vesicles from both the ER and TGN containing APP along with a concomitant increase in complex glycosylation and APP localization at the cell surface. In contrast, the FAD-linked PS1 mutant variants significantly reduce budding from the ER and TGN and result in decreased delivery of APP to the cell surface. These results suggest the possibility that FAD-linked PS1 variants increase Aβ production by decreasing intracellular transport of APP, prolonging the availability of APP for cleavage by β- and γ-secretases within the TGN. PS1 may regulate protein trafficking through its interaction with several cytosolic factors involved in the regulation of vesicular transport such as Rab11, Rab6 and Rab GDI. We have also found that PS1 interacts with phospholipase D1 (PLD1), a phospholipid-modifying enzyme regulating membrane trafficking events. This PS1-PLD1 interaction recruits PLD1 to the Golgi/TGN and thus potentially alters APP trafficking as PLD1 overexpression promotes budding of vesicles from the TGN containing APP and increases cell surface levels of APP.

34SorLA/LR11 is a type I membrane protein expressed in neurons and reduced in the brains of AD patients. Although the function of SorLA/LR11 is not known, its homology with sorting receptors that are involved with transport between the plasma membrane, endosomes and the Golgi suggests a protein trafficking function. Recently it was found that SorLA/LR11 overexpression redistributed APP to the Golgi, decreasing Aβ generation, while SorLA/LR11 knockout mice have increased levels of Aβ, as found in AD patients. Additionally, some inherited variants of the SorLA/LR11 gene were found to associate with late-onset AD.

35Low-density lipoprotein receptor-related protein (LRP) is a SorLA/LR11-related protein that binds to APP through Fe65, a cytoplasmic adaptor protein. LRP has been shown to bind, directly or indirectly, with Aβ to mediate its clearance. Antagonizing the extracellular interaction between cell-surface APP and LRP increased the level of cell surface APP while decreasing Aβ generation. Using an AD mouse model, expression of a functional LRP minireceptor in neurons resulted in increased memory deficits and higher Aβ levels in the aged mice. An LRP-related protein 1B (LRP1B) has a similar effect, binding APP at the plasma membrane, preventing APP internalization, and leading to decreased Aβ generation and increased sAPPα secretion.

Signal transduction

36Epidemiological evidence suggests that post-menopausal women receiving replacement therapy of the sex hormone estrogen have a reduced risk and delayed onset of AD while elderly women with reduced levels of circulating estrogen have an increased incidence of AD. The primary mechanism of estrogen's protection against AD development is still unclear. Several potential mechanisms have been proposed: (1) estrogen may act on interlukin 6 to antagonize inflammation; (2) the phenolic structure of estrogen may contribute to its antioxidant effect in cells; (3) estrogen may reduce the level of appolipoprotein E (ApoE), with the isoform ApoE4 being a strong risk factor for AD development; and (4) gonadal steroids may reduce the protein level of PS1 and thus γ-secretase activity.

37We have found that estrogen may reduce Aβ levels by stimulating the α-secretase pathway and thereby inhibit Aβ generation. Estrogen can stimulate the formation of APP-containing vesicles from the TGN in cell-free systems derived from both neuroblastomas and primary neurons. Interestingly, the stimulation of sAPPα secretion by estrogen can be blocked by a PKC inhibitor, suggesting the involvement of a PKC-dependent pathway. Indeed, phorbol ester's effect on sAPPα secretion and Aβ generation though activation of protein kinase C (PKC) has been known for a long time. PKC stimulates sAPPα secretion, reducing Aβ levels, even when the phosphorylation sites on APP are mutated or the entire cytoplasmic domain is deleted. While PKC can directly phosphorylate APP Ser655, it appears to affect APP metabolism by phosphorylating a different target. One potential target is a TGN phosphoprotein, resulting in transport of APP from the TGN to the cell surface. Our studies have shown that PKC increases the formation of APP-containing secretory vesicles from the TGN in a cell-free system. In support of this, protein kinase A (PKA) has similar effects on reducing Aβ generation and stimulating the budding of APP-containing vesicles from the TGN. The effects of PKC and PKA are additive, suggesting that while they both appear to act through stimulating vesicle formation from the TGN, the regulatory mechanisms involved are independent. Additionally, estrogen has been found to facilitate binding of Rab11 to the TGN membrane and a dominant negative Rab11 mutant abolishes the estrogen-regulated change in APP trafficking, leading to increased Aβ formation.

38The sex hormone testosterone decreases with age in older men and postmenopausal women. Animal model studies of testosterone treatments show neuroprotective and neuroexcitatory benefits along with improved cognitive performance. Some studies have suggested that testosterone exerts its beneficial effect through an aromatase-mediated conversion into estrogen. However, a recent study blocking the conversion of testosterone to estrogen found an estrogen-independent improvement in cognitive function and lowering of plaque formation along with a decrease in BACE1 mRNA, protein level, and activity. In addition, testosterone may also reduce the protein level of PS1.

Conclusion

39The overproduction and accumulation of Aβ in the brain are key pathogenic events in AD progression. In addition to Aβ, APP can be proteolyzed by different secretases and caspases. In this review we have discussed APP processing regulation and the physio/pathological functions of various APP metabolites. Further elucidation of APP metabolism will be important for identifying new potential therapies to reduce Aβ accumulation and combat AD.

References 211

1.
Levy-Lahad E Wasco W Poorkaj P Romano DM Oshima J Pettingell WH Yu CE Jondro PD Schmidt SD Wang K Candidate gene for the chromosome 1 familial Alzheimer's disease locusScience1995 269973977
Not in our library10.1126/science.7638622
2.
Sherrington R Rogaev EI Liang Y Rogaeva EA Levesque G Ikeda M Chi H Lin C Li G Holman K Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's diseaseNature1995 375754760
Not in our library10.1038/375754a0
3.
Goate A Chartier-Harlin MC Mullan M Brown J Crawford F Fidani L Giuffra L Haynes A Irving N James L Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's diseaseNature1991 349704706
Not in our library10.1038/349704a0
4.
Buee L Bussiere T Buee-Scherrer V Delacourte A Hof PR Tau protein isoforms, phosphorylation and role in neurodegenerative disordersBrain Res Brain Res Rev2000 3395130
Not in our library10.1016/s0165-0173(00)00019-9
5.
The role of tau in neurodegeneration · 2009
No notice
6.
Selkoe DJ The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's diseaseTrends Cell Biol1998 8447453
Not in our library10.1016/s0962-8924(98)01363-4
7.
Rohan de Silva HA Jen A Wickenden C Jen LS Wilkinson SL Patel AJ Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytesBrain Res Mol Brain Res1997 47147156
Not in our library10.1016/s0169-328x(97)00045-4
8.
Kang J Muller-Hill B Differential splicing of Alzheimer's disease amyloid A4 precursor RNA in rat tissues: PreA4(695) mRNA is predominantly produced in rat and human brainBiochem Biophys Res Commun1990 16611921200
Not in our library10.1016/0006-291x(90)90992-v
9.
Menendez-Gonzalez M Perez-Pinera P Martinez-Rivera M Calatayud MT Blazquez Menes B APP processing and the APP-KPI domain involvement in the amyloid cascadeNeurodegener Dis2005 2277283
Not in our library10.1159/000092315
10.
Bordji K Becerril-Ortega J Nicole O Buisson A Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ss productionJ Neurosci2010 301592715942
Not in our library10.1523/jneurosci.3021-10.2010
11.
Wasco W Bupp K Magendantz M Gusella JF Tanzi RE Solomon F Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursorProc Natl Acad Sci USA1992 891075810762
Not in our library10.1073/pnas.89.22.10758
12.
Wasco W Gurubhagavatula S Paradis MD Romano DM Sisodia SS Hyman BT Neve RL Tanzi RE Isolation and characterization of APLP2 encoding a homologue of the Alzheimer's associated amyloid beta protein precursorNat Genet1993 595100
Not in our library10.1038/ng0993-95
13.
Coulson EJ Paliga K Beyreuther K Masters CL What the evolution of the amyloid protein precursor supergene family tells us about its functionNeurochem Int2000 36175184
Not in our library10.1016/s0197-0186(99)00125-4
14.
Zheng H Jiang M Trumbauer ME Sirinathsinghji DJ Hopkins R Smith DW Heavens RP Dawson GR Boyce S Conner MW beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activityCell1995 81525531
Not in our library10.1016/0092-8674(95)90073-x
15.
Dawson GR Seabrook GR Zheng H Smith DW Graham S O'Dowd G Bowery BJ Boyce S Trumbauer ME Chen HY Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor proteinNeuroscience1999 90113
Not in our library10.1016/s0306-4522(98)00410-2
16.
von Koch CS Zheng H Chen H Trumbauer M Thinakaran G van der Ploeg LH Price DL Sisodia SS Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO miceNeurobiol Aging1997 18661669
Not in our library10.1016/s0197-4580(97)00151-6
17.
Heber S Herms J Gajic V Hainfellner J Aguzzi A Rulicke T von Kretzschmar H von Koch C Sisodia S Tremml P Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family membersJ Neurosci2000 2079517963
Not in our library10.1523/jneurosci.20-21-07951.2000
18.
Herms J Anliker B Heber S Ring S Fuhrmann M Kretzschmar H Sisodia S Muller U Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family membersEmbo J2004 2341064115
Not in our library10.1038/sj.emboj.7600390
19.
The amyloid precursor protein: beyond amyloid. · 2006
No notice
20.
Lorenzo A Yuan M Zhang Z Paganetti PA Sturchler-Pierrat C Staufenbiel M Mautino J Vigo FS Sommer B Yankner BA Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's diseaseNat Neurosci2000 3460464
Not in our library10.1038/74833
21.
Ho A Sudhof TC Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavageProc Natl Acad Sci USA2004 10125482553
Not in our library10.1073/pnas.0308655100
22.
Lourenco FC Galvan V Fombonne J Corset V Llambi F Muller U Bredesen DE Mehlen P Netrin-1 interacts with amyloid precursor protein and regulates amyloid-beta productionCell Death Differ2009 16655663
Not in our library10.1038/cdd.2008.191
23.
Yamazaki T Koo EH Selkoe DJ Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cellsJ Neurosci1997 1710041010
Not in our library10.1523/jneurosci.17-03-01004.1997
24.
Wang Y Ha Y The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domainMol Cell2004 15343353
Not in our library10.1016/j.molcel.2004.06.037
25.
Soba P Eggert S Wagner K Zentgraf H Siehl K Kreger S Lower A Langer A Merdes G Paro R Homo- and heterodimerization of APP family members promotes intercellular adhesionEmbo J2005 2436243634
Not in our library10.1038/sj.emboj.7600824
26.
Kamal A Stokin GB Yang Z Xia CH Goldstein LS Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-INeuron2000 28449459
Not in our library10.1016/s0896-6273(00)00124-0
27.
Kamal A Almenar-Queralt A LeBlanc JF Roberts EA Goldstein LS Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APPNature2001 414643648
Not in our library10.1038/414643a
28.
Lazarov O Morfini GA Lee EB Farah MH Szodorai A DeBoer SR Koliatsos VE Kins S Lee VM Wong PC Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisitedJ Neurosci2005 2523862395
Not in our library10.1523/jneurosci.3089-04.2005
29.
Liu Y Zhang YW Wang X Zhang H You X Liao FF Xu H Intracellular trafficking of presenilin 1 is regulated by beta-amyloid precursor protein and phospholipase D1J Biol Chem2009 2841214512152
Not in our library10.1074/jbc.m808497200
30.
Satpute-Krishnan P DeGiorgis JA Bearer EL Fast anterograde transport of herpes simplex virus: role for the amyloid precursor protein of alzheimer's diseaseAging Cell2003 2305318
Not in our library10.1046/j.1474-9728.2003.00069.x
31.
Satpute-Krishnan P DeGiorgis JA Conley MP Jang M Bearer EL A peptide zipcode sufficient for anterograde transport within amyloid precursor proteinProc Natl Acad Sci USA2006 1031653216537
Not in our library10.1073/pnas.0607527103
32.
Salehi A Delcroix JD Belichenko PV Zhan K Wu C Valletta JS Takimoto-Kimura R Kleschevnikov AM Sambamurti K Chung PP Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degenerationNeuron2006 512942
Not in our library10.1016/j.neuron.2006.05.022
33.
Wang B Yang L Wang Z Zheng H Amyolid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporterProc Natl Acad Sci USA2007 1041414014145
Not in our library10.1073/pnas.0704070104
34.
Xu H Sweeney D Wang R Thinakaran G Lo AC Sisodia SS Greengard P Gandy S Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formationProc Natl Acad Sci USA1997 9437483752
Not in our library10.1073/pnas.94.8.3748
35.
Hartmann T Bieger SC Bruhl B Tienari PJ Ida N Allsop D Roberts GW Masters CL Dotti CG Unsicker K Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptidesNat Med1997 310161020
Not in our library10.1038/nm0997-1016
36.
Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β-amyloid peptides · 1999
Not checked
37.
Sisodia SS Beta-amyloid precursor protein cleavage by a membrane-bound proteaseProc Natl Acad Sci USA1992 8960756079
Not in our library10.1073/pnas.89.13.6075
38.
Nordstedt C Caporaso GL Thyberg J Gandy SE Greengard P Identification of the Alzheimer beta/A4 amyloid precursor protein in clathrin-coated vesicles purified from PC12 cellsJ Biol Chem1993 268608612
Not in our library
39.
Caporaso GL Takei K Gandy SE Matteoli M Mundigl O Greengard P De Camilli P Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer beta/A4 amyloid precursor proteinJ Neurosci1994 1431223138
Not in our library10.1523/jneurosci.14-05-03122.1994
40.
Haass C Hung AY Schlossmacher MG Teplow DB Selkoe DJ beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanismsJ Biol Chem1993 26830213024
Not in our library
41.
Haass C Hung AY Schlossmacher MG Oltersdorf T Teplow DB Selkoe DJ Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related moleculesAnn N Y Acad Sci1993 695109116
Not in our library10.1111/j.1749-6632.1993.tb23037.x
42.
Furukawa K Sopher BL Rydel RE Begley JG Pham DG Martin GM Fox M Mattson MP Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domainJ Neurochem1996 6718821896
Not in our library10.1046/j.1471-4159.1996.67051882.x
43.
Mattson MP Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivativesPhysiol Rev1997 7710811132
Not in our library10.1152/physrev.1997.77.4.1081
44.
Han P Dou F Li F Zhang X Zhang YW Zheng H Lipton SA Xu H Liao FF Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylationJ Neurosci2005 251154211552
Not in our library10.1523/jneurosci.3831-05.2005
45.
Roberts SB Ripellino JA Ingalls KM Robakis NK Felsenstein KM Non-amyloidogenic cleavage of the beta-amyloid precursor protein by an integral membrane metalloendopeptidaseJ Biol Chem1994 26931113116
Not in our library
46.
Black RA Rauch CT Kozlosky CJ Peschon JJ Slack JL Wolfson MF Castner BJ Stocking KL Reddy P Srinivasan S A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cellsNature1997 385729733
Not in our library10.1038/385729a0
47.
Buxbaum JD Liu KN Luo Y Slack JL Stocking KL Peschon JJ Johnson RS Castner BJ Cerretti DP Black RA Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursorJ Biol Chem1998 2732776527767
Not in our library10.1074/jbc.273.43.27765
48.
Blacker M Noe MC Carty TJ Goodyer CG LeBlanc AC Effect of tumor necrosis factor-alpha converting enzyme (TACE) and metalloprotease inhibitor on amyloid precursor protein metabolism in human neuronsJ Neurochem2002 8313491357
Not in our library10.1046/j.1471-4159.2002.01228.x
49.
Kuhn PH Wang H Dislich B Colombo A Zeitschel U Ellwart JW Kremmer E Rossner S Lichtenthaler SF ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neuronsEmbo J2010 2930203032
Not in our library10.1038/emboj.2010.167
50.
Merlos-Suarez A Ruiz-Paz S Baselga J Arribas J Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzymeJ Biol Chem2001 2764851048517
Not in our library10.1074/jbc.m103488200
51.
Koike H Tomioka S Sorimachi H Saido TC Maruyama K Okuyama A Fujisawa-Sehara A Ohno S Suzuki K Ishiura S Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor proteinBiochem J1999 343Pt 2371375
Not in our library10.1042/0264-6021:3430371
52.
Lopez-Perez E Zhang Y Frank SJ Creemers J Seidah N Checler F Constitutive alpha-secretase cleavage of the beta-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the pro-hormone convertase 7 and the disintegrin metalloprotease ADAM10J Neurochem2001 7615321539
Not in our library10.1046/j.1471-4159.2001.00180.x
53.
Lammich S Kojro E Postina R Gilbert S Pfeiffer R Jasionowski M Haass C Fahrenholz F Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloproteaseProc Natl Acad Sci USA1999 9639223927
Not in our library10.1073/pnas.96.7.3922
54.
Jorissen E Prox J Bernreuther C Weber S Schwanbeck R Serneels L Snellinx A Craessaerts K Thathiah A Tesseur I The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortexJ Neurosci2010 3048334844
Not in our library10.1523/jneurosci.5221-09.2010
55.
Colciaghi F Borroni B Pastorino L Marcello E Zimmermann M Cattabeni F Padovani A Di Luca M [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patientsMol Med2002 86774
Not in our library
56.
Tyler SJ Dawbarn D Wilcock GK Allen SJ alpha- and beta-secretase: profound changes in Alzheimer's diseaseBiochem Biophys Res Commun2002 299373376
Not in our library10.1016/s0006-291x(02)02635-9
57.
Caille I Allinquant B Dupont E Bouillot C Langer A Muller U Prochiantz A Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zoneDevelopment2004 13121732181
Not in our library10.1242/dev.01103
58.
Ohsawa I Takamura C Morimoto T Ishiguro M Kohsaka S Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cellsEur J Neurosci1999 1119071913
Not in our library10.1046/j.1460-9568.1999.00601.x
59.
Ma T Zhao Y Kwak YD Yang Z Thompson R Luo Z Xu H Liao FF Statin's excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signalingJ Neurosci2009 291122611236
Not in our library10.1523/jneurosci.6150-08.2009
60.
Marcade M Bourdin J Loiseau N Peillon H Rayer A Drouin D Schweighoffer F Desire L Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processingJ Neurochem2008 106392404
Not in our library10.1111/j.1471-4159.2008.05396.x
61.
Levites Y Amit T Mandel S Youdim MB Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallateFaseb J2003 17952954
Not in our library10.1096/fj.02-0881fje
62.
Ring S Weyer SW Kilian SB Waldron E Pietrzik CU Filippov MA Herms J Buchholz C Eckman CB Korte M The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient miceJ Neurosci2007 2778177826
Not in our library10.1523/jneurosci.1026-07.2007
63.
Sinha S Anderson JP Barbour R Basi GS Caccavello R Davis D Doan M Dovey HF Frigon N Hong J Purification and cloning of amyloid precursor protein beta-secretase from human brainNature1999 402537540
Not in our library10.1038/990114
64.
Vassar R Bennett BD Babu-Khan S Kahn S Mendiaz EA Denis P Teplow DB Ross S Amarante P Loeloff R Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACEScience1999 286735741
Not in our library10.1126/science.286.5440.735
65.
Yan R Bienkowski MJ Shuck ME Miao H Tory MC Pauley AM Brashier JR Stratman NC Mathews WR Buhl AE Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activityNature1999 402533537
Not in our library10.1038/990107
66.
Lau KF McLoughlin DM Standen C Miller CC X11 alpha and x11 beta interact with presenilin-1 via their PDZ domainsMol Cell Neurosci2000 16557565
Not in our library10.1006/mcne.2000.0898
67.
Cai H Wang Y McCarthy D Wen H Borchelt DR Price DL Wong PC BACE1 is the major beta-secretase for generation of Abeta peptides by neuronsNat Neurosci2001 4233234
Not in our library10.1038/85064
68.
Creemers JW Ines Dominguez D Plets E Serneels L Taylor NA Multhaup G Craessaerts K Annaert W De Strooper B Processing of beta-secretase by furin and other members of the proprotein convertase familyJ Biol Chem2001 27642114217
Not in our library10.1074/jbc.m006947200
69.
Bennett BD Denis P Haniu M Teplow DB Kahn S Louis JC Citron M Vassar R A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's beta-secretaseJ Biol Chem2000 2753771237717
Not in our library10.1074/jbc.m005339200
70.
Walter J Fluhrer R Hartung B Willem M Kaether C Capell A Lammich S Multhaup G Haass C Phosphorylation regulates intracellular trafficking of beta-secretaseJ Biol Chem2001 2761463414641
Not in our library10.1074/jbc.m011116200
71.
Huse JT Pijak DS Leslie GJ Lee VM Doms RW Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretaseJ Biol Chem2000 2753372933737
Not in our library10.1074/jbc.m004175200
72.
Huse JT Liu K Pijak DS Carlin D Lee VM Doms RW Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brainJ Biol Chem2002 2771627816284
Not in our library10.1074/jbc.m111141200
73.
He W Lu Y Qahwash I Hu XY Chang A Yan R Reticulon family members modulate BACE1 activity and amyloid-beta peptide generationNat Med2004 10959965
Not in our library10.1038/nm1088
74.
Murayama KS Kametani F Saito S Kume H Akiyama H Araki W Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid beta-proteinEur J Neurosci2006 2412371244
Not in our library10.1111/j.1460-9568.2006.05005.x
75.
Shi Q Prior M He W Tang X Hu X Yan R Reduced amyloid deposition in mice overexpressing RTN3 is adversely affected by preformed dystrophic neuritesJ Neurosci2009 2991639173
Not in our library10.1523/jneurosci.5741-08.2009
76.
He X Li F Chang WP Tang J GGA proteins mediate the recycling pathway of memapsin 2 (BACE)J Biol Chem2005 2801169611703
Not in our library10.1074/jbc.m411296200
77.
Tesco G Koh YH Kang EL Cameron AN Das S Sena-Esteves M Hiltunen M Yang SH Zhong Z Shen Y Depletion of GGA3 stabilizes BACE and enhances beta-secretase activityNeuron2007 54721737
Not in our library10.1016/j.neuron.2007.05.012
78.
Wahle T Prager K Raffler N Haass C Famulok M Walter J GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi networkMol Cell Neurosci2005 29453461
Not in our library10.1016/j.mcn.2005.03.014
79.
Luo Y Bolon B Kahn S Bennett BD Babu-Khan S Denis P Fan W Kha H Zhang J Gong Y Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generationNat Neurosci2001 4231232
Not in our library10.1038/85059
80.
Ohno M Sametsky EA Younkin LH Oakley H Younkin SG Citron M Vassar R Disterhoft JF BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's diseaseNeuron2004 412733
Not in our library10.1016/s0896-6273(03)00810-9
81.
Ohno M Cole SL Yasvoina M Zhao J Citron M Berry R Disterhoft JF Vassar R BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic miceNeurobiol Dis2007 26134145
Not in our library10.1016/j.nbd.2006.12.008
82.
Yang LB Lindholm K Yan R Citron M Xia W Yang XL Beach T Sue L Wong P Price D Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer diseaseNat Med2003 934
Not in our library10.1038/nm0103-3
83.
Johnston JA Liu WW Todd SA Coulson DT Murphy S Irvine GB Passmore AP Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's diseaseBiochem Soc Trans2005 3310961100
Not in our library10.1042/bst20051096
84.
Dominguez D Tournoy J Hartmann D Huth T Cryns K Deforce S Serneels L Camacho IE Marjaux E Craessaerts K Phenotypic and biochemical analyses of BACE1- and BACE2-deficient miceJ Biol Chem2005 2803079730806
Not in our library10.1074/jbc.m505249200
85.
Hu X Hicks CW He W Wong P Macklin WB Trapp BD Yan R Bace1 modulates myelination in the central and peripheral nervous systemNat Neurosci2006 915201525
Not in our library10.1038/nn1797
86.
Willem M Garratt AN Novak B Citron M Kaufmann S Rittger A DeStrooper B Saftig P Birchmeier C Haass C Control of peripheral nerve myelination by the beta-secretase BACE1Science2006 314664666
Not in our library10.1126/science.1132341
87.
Vassar R Kovacs DM Yan R Wong PC The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potentialJ Neurosci2009 291278712794
Not in our library10.1523/jneurosci.3657-09.2009
88.
Solans A Estivill X de La Luna S A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein beta-secretaseCytogenet Cell Genet2000 89177184
Not in our library10.1159/000015608
89.
Hussain I Powell DJ Howlett DR Chapman GA Gilmour L Murdock PR Tew DG Meek TD Chapman C Schneider K ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase siteMol Cell Neurosci2000 16609619
Not in our library10.1006/mcne.2000.0884
90.
Bennett BD Babu-Khan S Loeloff R Louis JC Curran E Citron M Vassar R Expression analysis of BACE2 in brain and peripheral tissuesJ Biol Chem2000 2752064720651
Not in our library10.1074/jbc.m002688200
91.
Yan R Munzner JB Shuck ME Bienkowski MJ BACE2 functions as an alternative alpha-secretase in cellsJ Biol Chem2001 2763401934027
Not in our library10.1074/jbc.m105583200
92.
Hook V Toneff T Bogyo M Greenbaum D Medzihradszky KF Neveu J Lane W Hook G Reisine T Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's diseaseBiol Chem2005 386931940
Not in our library10.1515/bc.2005.108
93.
Hook VY Kindy M Reinheckel T Peters C Hook G Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor proteinBiochem Biophys Res Commun2009 386284288
Not in our library10.1016/j.bbrc.2009.05.131
94.
Nikolaev A McLaughlin T O'Leary DD Tessier-Lavigne M APP binds DR6 to trigger axon pruning and neuron death via distinct caspasesNature2009 457981989
Not in our library10.1038/nature07767
95.
Li H Wang B Wang Z Guo Q Tabuchi K Hammer RE Sudhof TC Zheng H Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APPProc Natl Acad Sci USA2010 1071736217367
Not in our library10.1073/pnas.1012568107
96.
Yankner BA Dawes LR Fisher S Villa-Komaroff L Oster-Granite ML Neve RL Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's diseaseScience1989 245417420
Not in our library10.1126/science.2474201
97.
Oster-Granite ML McPhie DL Greenan J Neve RL Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor proteinJ Neurosci1996 1667326741
Not in our library10.1523/jneurosci.16-21-06732.1996
98.
Zhao G Mao G Tan J Dong Y Cui MZ Kim SH Xu X Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor proteinJ Biol Chem2004 2795064750650
Not in our library10.1074/jbc.c400473200
99.
Zhao G Tan J Mao G Cui MZ Xu X The same gamma-secretase accounts for the multiple intramembrane cleavages of APPJ Neurochem2007 10012341246
Not in our library10.1111/j.1471-4159.2006.04302.x
100.
Sastre M Steiner H Fuchs K Capell A Multhaup G Condron MM Teplow DB Haass C Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of NotchEMBO Rep2001 2835841
Not in our library10.1093/embo-reports/kve180
101.
Weidemann A Eggert S Reinhard FB Vogel M Paliga K Baier G Masters CL Beyreuther K Evin G A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processingBiochemistry2002 4128252835
Not in our library10.1021/bi015794o
102.
Kimberly WT LaVoie MJ Ostaszewski BL Ye W Wolfe MS Selkoe DJ Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2Proc Natl Acad Sci USA2003 10063826387
Not in our library10.1073/pnas.1037392100
103.
Takasugi N Tomita T Hayashi I Tsuruoka M Niimura M Takahashi Y Thinakaran G Iwatsubo T The role of presenilin cofactors in the gamma-secretase complexNature2003 422438441
Not in our library10.1038/nature01506
104.
Kim J Schekman R The ins and outs of presenilin 1 membrane topologyProc Natl Acad Sci USA2004 101905906
Not in our library10.1073/pnas.0307297101
105.
Borchelt DR Thinakaran G Eckman CB Lee MK Davenport F Ratovitsky T Prada CM Kim G Seekins S Yager D Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivoNeuron1996 1710051013
Not in our library10.1016/s0896-6273(00)80230-5
106.
Li YM Lai MT Xu M Huang Q DiMuzio-Mower J Sardana MK Shi XP Yin KC Shafer JA Gardell SJ Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized stateProc Natl Acad Sci USA2000 9761386143
Not in our library10.1073/pnas.110126897
107.
Ahn K Shelton CC Tian Y Zhang X Gilchrist ML Sisodia SS Li YM Activation and intrinsic {gamma}-secretase activity of presenilin 1Proc Natl Acad Sci USA2010
Not in our library10.1073/pnas.1013246107
108.
Luo WJ Wang H Li H Kim BS Shah S Lee HJ Thinakaran G Kim TW Yu G Xu H PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1J Biol Chem2003 27878507854
Not in our library10.1074/jbc.c200648200
109.
Francis R McGrath G Zhang J Ruddy DA Sym M Apfeld J Nicoll M Maxwell M Hai B Ellis MC aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulationDev Cell2002 38597
Not in our library10.1016/s1534-5807(02)00189-2
110.
Goutte C Tsunozaki M Hale VA Priess JR APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryosProc Natl Acad Sci USA2002 99775779
Not in our library10.1073/pnas.022523499
111.
Edbauer D Winkler E Regula JT Pesold B Steiner H Haass C Reconstitution of gamma-secretase activityNat Cell Biol2003 5486488
Not in our library10.1038/ncb960
112.
Greenfield JP Xu H Greengard P Gandy S Seeger M Generation of the amyloid-beta peptide N terminus in Saccharomyces cerevisiae expressing human Alzheimer's amyloid-beta precursor proteinJ Biol Chem1999 2743384333846
Not in our library10.1074/jbc.274.48.33843
113.
Zhou S Zhou H Walian PJ Jap BK CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide productionProc Natl Acad Sci USA2005 10274997504
Not in our library10.1073/pnas.0502768102
114.
Chen F Hasegawa H Schmitt-Ulms G Kawarai T Bohm C Katayama T Gu Y Sanjo N Glista M Rogaeva E TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activityNature2006 44012081212
Not in our library10.1038/nature04667
115.
Pardossi-Piquard R Bohm C Chen F Kanemoto S Checler F Schmitt-Ulms G St George-Hyslop P Fraser PE TMP21 transmembrane domain regulates gamma-secretase cleavageJ Biol Chem2009 2842863428641
Not in our library10.1074/jbc.m109.059345
116.
Vetrivel KS Gong P Bowen JW Cheng H Chen Y Carter M Nguyen PD Placanica L Wieland FT Li YM Dual roles of the transmembrane protein p23/TMP21 in the modulation of amyloid precursor protein metabolismMol Neurodegener2007 24
Not in our library10.1186/1750-1326-2-4
117.
He G Luo W Li P Remmers C Netzer WJ Hendrick J Bettayeb K Flajolet M Gorelick F Wennogle LP Gamma-secretase activating protein is a therapeutic target for Alzheimer's diseaseNature2010 4679598
Not in our library10.1038/nature09325
118.
Cupers P Bentahir M Craessaerts K Orlans I Vanderstichele H Saftig P De Strooper B Annaert W The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor proteinJ Cell Biol2001 154731740
Not in our library10.1083/jcb.200104045
119.
Kovacs DM Fausett HJ Page KJ Kim TW Moir RD Merriam DE Hollister RD Hallmark OG Mancini R Felsenstein KM Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cellsNat Med1996 2224229
Not in our library10.1038/nm0296-224
120.
Haass C De Strooper B The presenilins in Alzheimer's disease--proteolysis holds the keyScience1999 286916919
Not in our library10.1126/science.286.5441.916
121.
Wang R Tang P Wang P Boissy RE Zheng H Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutationProc Natl Acad Sci USA2006 103353358
Not in our library10.1073/pnas.0509822102
122.
Pathological and physiological functions of presenilins · 2006
No notice
123.
Tarassishin L Yin YI Bassit B Li YM Processing of Notch and amyloid precursor protein by gamma-secretase is spatially distinctProc Natl Acad Sci USA2004 1011705017055
Not in our library10.1073/pnas.0408007101
124.
Kopan R Schroeter EH Weintraub H Nye JS Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domainProc Natl Acad Sci USA1996 9316831688
Not in our library10.1073/pnas.93.4.1683
125.
Schroeter EH Kisslinger JA Kopan R Notch-1 signalling requires ligand-induced proteolytic release of intracellular domainNature1998 393382386
Not in our library10.1038/30756
126.
Sardi SP Murtie J Koirala S Patten BA Corfas G Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brainCell2006 127185197
Not in our library10.1016/j.cell.2006.07.037
127.
Baek SH Ohgi KA Rose DW Koo EH Glass CK Rosenfeld MG Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor proteinCell2002 1105567
Not in our library10.1016/s0092-8674(02)00809-7
128.
Kim HS Kim EM Lee JP Park CH Kim S Seo JH Chang KA Yu E Jeong SJ Chong YH C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expressionFaseb J2003 1719511953
Not in our library10.1096/fj.03-0106fje
129.
Pardossi-Piquard R Petit A Kawarai T Sunyach C Alves da Costa C Vincent B Ring S D'Adamio L Shen J Muller U Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLPNeuron2005 46541554
Not in our library10.1016/j.neuron.2005.04.008
130.
von Rotz RC Kohli BM Bosset J Meier M Suzuki T Nitsch RM Konietzko U The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursorJ Cell Sci2004 11744354448
Not in our library10.1242/jcs.01323
131.
Zhang YW Wang R Liu Q Zhang H Liao FF Xu H Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expressionProc Natl Acad Sci USA2007 1041061310618
Not in our library10.1073/pnas.0703903104
132.
Liu Q Zerbinatti CV Zhang J Hoe HS Wang B Cole SL Herz J Muglia L Bu G Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1Neuron2007 566678
Not in our library10.1016/j.neuron.2007.08.008
133.
Giliberto L Zhou D Weldon R Tamagno E De Luca P Tabaton M D'Adamio L Evidence that the Amyloid beta Precursor Protein-intracellular domain lowers the stress threshold of neurons and has a "regulated" transcriptional roleMol Neurodegener2008 312
Not in our library10.1186/1750-1326-3-12
134.
Kinoshita A Whelan CM Berezovska O Hyman BT The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cellsJ Biol Chem2002 2772853028536
Not in our library10.1074/jbc.m203372200
135.
The interactome of the amyloid β precursor protein family members is shaped by phosphorylation of their intracellular domains · 2009
Not checked
136.
Park SA Shaked GM Bredesen DE Koo EH Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor proteinBiochem Biophys Res Commun2009 388450455
Not in our library10.1016/j.bbrc.2009.08.042
137.
Gervais FG Xu D Robertson GS Vaillancourt JP Zhu Y Huang J LeBlanc A Smith D Rigby M Shearman MS Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formationCell1999 97395406
Not in our library10.1016/s0092-8674(00)80748-5
138.
Bredesen DE Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependenceMol Neurodegener2009 427
Not in our library10.1186/1750-1326-4-27
139.
Soriano S Lu DC Chandra S Pietrzik CU Koo EH The amyloidogenic pathway of amyloid precursor protein (APP) is independent of its cleavage by caspasesJ Biol Chem2001 2762904529050
Not in our library10.1074/jbc.m102456200
140.
Lu DC Soriano S Bredesen DE Koo EH Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicityJ Neurochem2003 87733741
Not in our library10.1046/j.1471-4159.2003.02059.x
141.
Galvan V Gorostiza OF Banwait S Ataie M Logvinova AV Sitaraman S Carlson E Sagi SA Chevallier N Jin K Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664Proc Natl Acad Sci USA2006 10371307135
Not in our library10.1073/pnas.0509695103
142.
Alzheimer's disease: synaptic dysfunction and Aβ · 2009
No notice
143.
Burdick D Soreghan B Kwon M Kosmoski J Knauer M Henschen A Yates J Cotman C Glabe C Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogsJ Biol Chem1992 267546554
Not in our library
144.
Scheuner D Eckman C Jensen M Song X Citron M Suzuki N Bird TD Hardy J Hutton M Kukull W Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's diseaseNat Med1996 2864870
Not in our library10.1038/nm0896-864
145.
Jarrett JT Berger EP Lansbury PT Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's diseaseBiochemistry1993 3246934697
Not in our library10.1021/bi00069a001
146.
Iwatsubo T Odaka A Suzuki N Mizusawa H Nukina N Ihara Y Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)Neuron1994 134553
Not in our library10.1016/0896-6273(94)90458-8
147.
Gouras GK Tsai J Naslund J Vincent B Edgar M Checler F Greenfield JP Haroutunian V Buxbaum JD Xu H Intraneuronal Abeta42 accumulation in human brainAm J Pathol2000 1561520
Not in our library10.1016/s0002-9440(10)64700-1
148.
Gyure KA Durham R Stewart WF Smialek JE Troncoso JC Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndromeArch Pathol Lab Med2001 125489492
Not in our library10.5858/2001-125-0489-iaapdo
149.
Mori C Spooner ET Wisniewsk KE Wisniewski TM Yamaguch H Saido TC Tolan DR Selkoe DJ Lemere CA Intraneuronal Abeta42 accumulation in Down syndrome brainAmyloid2002 988102
Not in our library
150.
Oddo S Caccamo A Shepherd JD Murphy MP Golde TE Kayed R Metherate R Mattson MP Akbari Y LaFerla FM Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunctionNeuron2003 39409421
Not in our library10.1016/s0896-6273(03)00434-3
151.
Oddo S Caccamo A Smith IF Green KN LaFerla FM A dynamic relationship between intracellular and extracellular pools of AbetaAm J Pathol2006 168184194
Not in our library10.2353/ajpath.2006.050593
152.
Oakley H Cole SL Logan S Maus E Shao P Craft J Guillozet-Bongaarts A Ohno M Disterhoft J Van Eldik L Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formationJ Neurosci2006 261012910140
Not in our library10.1523/jneurosci.1202-06.2006
153.
Espana J Gimenez-Llort L Valero J Minano A Rabano A Rodriguez-Alvarez J LaFerla FM Saura CA Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic miceBiol Psychiatry2010 67513521
Not in our library10.1016/j.biopsych.2009.06.015
154.
Endocytic pathways mediating oligomeric Aβ42 neurotoxicity · 2010
Not checked
155.
Friedrich RP Tepper K Ronicke R Soom M Westermann M Reymann K Kaether C Fandrich M Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicityProc Natl Acad Sci USA2010 10719421947
Not in our library10.1073/pnas.0904532106
156.
Seubert P Vigo-Pelfrey C Esch F Lee M Dovey H Davis D Sinha S Schlossmacher M Whaley J Swindlehurst C Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluidsNature1992 359325327
Not in our library10.1038/359325a0
157.
Haass C Schlossmacher MG Hung AY Vigo-Pelfrey C Mellon A Ostaszewski BL Lieberburg I Koo EH Schenk D Teplow DB Amyloid beta-peptide is produced by cultured cells during normal metabolismNature1992 359322325
Not in our library10.1038/359322a0
158.
Puzzo D Privitera L Leznik E Fa M Staniszewski A Palmeri A Arancio O Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampusJ Neurosci2008 281453714545
Not in our library10.1523/jneurosci.2692-08.2008
159.
Morley JE Farr SA Banks WA Johnson SN Yamada KA Xu L A physiological role for amyloid-beta protein:enhancement of learning and memoryJ Alzheimers Dis2010 19441449
Not in our library10.3233/jad-2009-1230
160.
Plant LD Boyle JP Smith IF Peers C Pearson HA The production of amyloid beta peptide is a critical requirement for the viability of central neuronsJ Neurosci2003 2355315535
Not in our library10.1523/jneurosci.23-13-05531.2003
161.
Plant LD Webster NJ Boyle JP Ramsden M Freir DB Peers C Pearson HA Amyloid beta peptide as a physiological modulator of neuronal 'A'-type K+ currentNeurobiol Aging2006 2716731683
Not in our library10.1016/j.neurobiolaging.2005.09.038
162.
Minniti AN Rebolledo DL Grez PM Fadic R Aldunate R Volitakis I Cherny RA Opazo C Masters C Bush AI Intracellular amyloid formation in muscle cells of Abeta-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxificationMol Neurodegener2009 42
Not in our library10.1186/1750-1326-4-2
163.
King GD Scott Turner R Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?Exp Neurol2004 185208219
Not in our library10.1016/j.expneurol.2003.10.011
164.
Rogelj B Mitchell JC Miller CC McLoughlin DM The X11/Mint family of adaptor proteinsBrain Res Rev2006 52305315
Not in our library10.1016/j.brainresrev.2006.04.005
165.
Borg JP Ooi J Levy E Margolis B The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor proteinMol Cell Biol1996 1662296241
Not in our library10.1128/mcb.16.11.6229
166.
Borg JP Yang Y De Taddeo-Borg M Margolis B Turner RS The X11alpha protein slows cellular amyloid precursor protein processing and reduces Abeta40 and Abeta42 secretionJ Biol Chem1998 2731476114766
Not in our library10.1074/jbc.273.24.14761
167.
Salcini AE Chen H Iannolo G De Camilli P Di Fiore PP Epidermal growth factor pathway substrate 15, Eps15Int J Biochem Cell Biol1999 31805809
Not in our library10.1016/s1357-2725(99)00042-4
168.
Sorkin A Cargo recognition during clathrin-mediated endocytosis: a team effortCurr Opin Cell Biol2004 16392399
Not in our library10.1016/j.ceb.2004.06.001
169.
Maldonado-Baez L Wendland B Endocytic adaptors: recruiters, coordinators and regulatorsTrends Cell Biol2006 16505513
Not in our library10.1016/j.tcb.2006.08.001
170.
Chyung JH Selkoe DJ Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surfaceJ Biol Chem2003 2785103551043
Not in our library10.1074/jbc.m304989200
171.
Carey RM Balcz BA Lopez-Coviella I Slack BE Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta proteinBMC Cell Biol2005 630
Not in our library10.1186/1471-2121-6-30
172.
Cai D Leem JY Greenfield JP Wang P Kim BS Wang R Lopes KO Kim SH Zheng H Greengard P Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor proteinJ Biol Chem2003 27834463454
Not in our library10.1074/jbc.m209065200
173.
Dumanchin C Czech C Campion D Cuif MH Poyot T Martin C Charbonnier F Goud B Pradier L Frebourg T Presenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transportHum Mol Genet1999 812631269
Not in our library10.1093/hmg/8.7.1263
174.
Scheper W Zwart R Sluijs P Annaert W Gool WA Baas F Alzheimer's presenilin 1 is a putative membrane receptor for rab GDP dissociation inhibitorHum Mol Genet2000 9303310
Not in our library10.1093/hmg/9.2.303
175.
Scheper W Zwart R Baas F Rab6 membrane association is dependent of Presenilin 1 and cellular phosphorylation eventsBrain Res Mol Brain Res2004 1221723
Not in our library10.1016/j.molbrainres.2003.11.013
176.
Cai D Netzer WJ Zhong M Lin Y Du G Frohman M Foster DA Sisodia SS Xu H Gorelick FS Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formationProc Natl Acad Sci USA2006 10319411946
Not in our library10.1073/pnas.0510708103
177.
Cai D Zhong M Wang R Netzer WJ Shields D Zheng H Sisodia SS Foster DA Gorelick FS Xu H Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neuronsProc Natl Acad Sci USA2006 10319361940
Not in our library10.1073/pnas.0510710103
178.
Scherzer CR Offe K Gearing M Rees HD Fang G Heilman CJ Schaller C Bujo H Levey AI Lah JJ Loss of apolipoprotein E receptor LR11 in Alzheimer diseaseArch Neurol2004 6112001205
Not in our library10.1001/archneur.61.8.1200
179.
Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain · 2009
Not checked
180.
Yamazaki H Bujo H Kusunoki J Seimiya K Kanaki T Morisaki N Schneider WJ Saito Y Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family memberJ Biol Chem1996 2712476124768
Not in our library10.1074/jbc.271.11.6483
181.
Jacobsen L Madsen P Moestrup SK Lund AH Tommerup N Nykjaer A Sottrup-Jensen L Gliemann J Petersen CM Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptor-associated proteinJ Biol Chem1996 2713137931383
Not in our library10.1074/jbc.271.49.31379
182.
Andersen OM Reiche J Schmidt V Gotthardt M Spoelgen R Behlke J von Arnim CA Breiderhoff T Jansen P Wu X Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor proteinProc Natl Acad Sci USA2005 1021346113466
Not in our library10.1073/pnas.0503689102
183.
Rogaeva E Meng Y Lee JH Gu Y Kawarai T Zou F Katayama T Baldwin CT Cheng R Hasegawa H The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer diseaseNat Genet2007 39168177
Not in our library10.1038/ng1943
184.
Trommsdorff M Borg JP Margolis B Herz J Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor proteinJ Biol Chem1998 2733355633560
Not in our library10.1074/jbc.273.50.33556
185.
Narita M Holtzman DM Schwartz AL Bu G Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related proteinJ Neurochem1997 6919041911
Not in our library10.1046/j.1471-4159.1997.69051904.x
186.
Deane R Wu Z Sagare A Davis J Du Yan S Hamm K Xu F Parisi M LaRue B Hu HW LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoformsNeuron2004 43333344
Not in our library10.1016/j.neuron.2004.07.017
187.
Ulery PG Beers J Mikhailenko I Tanzi RE Rebeck GW Hyman BT Strickland DK Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's diseaseJ Biol Chem2000 27574107415
Not in our library10.1074/jbc.275.10.7410
188.
Zerbinatti CV Wozniak DF Cirrito J Cam JA Osaka H Bales KR Zhuo M Paul SM Holtzman DM Bu G Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related proteinProc Natl Acad Sci USA2004 10110751080
Not in our library10.1073/pnas.0305803101
189.
Cam JA Zerbinatti CV Knisely JM Hecimovic S Li Y Bu G The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide productionJ Biol Chem2004 2792963929646
Not in our library10.1074/jbc.m313893200
190.
Tang MX Jacobs D Stern Y Marder K Schofield P Gurland B Andrews H Mayeux R Effect of oestrogen during menopause on risk and age at onset of Alzheimer's diseaseLancet1996 348429432
Not in our library10.1016/s0140-6736(96)03356-9
191.
Waring SC Rocca WA Petersen RC O'Brien PC Tangalos EG Kokmen E Postmenopausal estrogen replacement therapy and risk of AD: a population-based studyNeurology1999 52965970
Not in our library10.1212/wnl.52.5.965
192.
Baldereschi M Di Carlo A Lepore V Bracco L Maggi S Grigoletto F Scarlato G Amaducci L Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on AgingNeurology1998 509961002
Not in our library10.1212/wnl.50.4.996
193.
Paganini-Hill A Estrogen replacement therapy--something to smile aboutCompend Contin Educ Dent Suppl1998 S48
Not in our library
194.
Wise PM Dubal DB Wilson ME Rau SW Bottner M Rosewell KL Estradiol is a protective factor in the adult and aging brain: understanding of mechanisms derived from in vivo and in vitro studiesBrain Res Brain Res Rev2001 37313319
Not in our library10.1016/s0165-0173(01)00136-9
195.
Colton CA Brown CM Vitek MP Sex steroids, APOE genotype and the innate immune systemNeurobiol Aging2005 26363372
Not in our library10.1016/j.neurobiolaging.2004.08.001
196.
Ghosh S Thakur MK PS1 expression is downregulated by gonadal steroids in adult mouse brainNeurochem Res2008 33365369
Not in our library10.1007/s11064-007-9424-8
197.
Greenfield JP Leung LW Cai D Kaasik K Gross RS Rodriguez-Boulan E Greengard P Xu H Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesisJ Biol Chem2002 2771212812136
Not in our library10.1074/jbc.m110009200
198.
Xu H Gouras GK Greenfield JP Vincent B Naslund J Mazzarelli L Fried G Jovanovic JN Seeger M Relkin NR Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptidesNat Med1998 4447451
Not in our library10.1038/nm0498-447
199.
Xu H Wang R Zhang YW Zhang X Estrogen, beta-amyloid metabolism/trafficking, and Alzheimer's diseaseAnn N Y Acad Sci2006 1089324342
Not in our library10.1196/annals.1386.036
200.
Zhang S Huang Y Zhu YC Yao T Estrogen stimulates release of secreted amyloid precursor protein from primary rat cortical neurons via protein kinase C pathwayActa Pharmacol Sin2005 26171176
Not in our library10.1111/j.1745-7254.2005.00538.x
201.
Buxbaum JD Gandy SE Cicchetti P Ehrlich ME Czernik AJ Fracasso RP Ramabhadran TV Unterbeck AJ Greengard P Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylationProc Natl Acad Sci USA1990 8760036006
Not in our library10.1073/pnas.87.15.6003
202.
Caporaso GL Gandy SE Buxbaum JD Ramabhadran TV Greengard P Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor proteinProc Natl Acad Sci USA1992 8930553059
Not in our library10.1073/pnas.89.7.3055
203.
Gillespie SL Golde TE Younkin SG Secretory processing of the Alzheimer amyloid beta/A4 protein precursor is increased by protein phosphorylationBiochem Biophys Res Commun1992 18712851290
Not in our library10.1016/0006-291x(92)90442-n
204.
Hung AY Haass C Nitsch RM Qiu WQ Citron M Wurtman RJ Growdon JH Selkoe DJ Activation of protein kinase C inhibits cellular production of the amyloid beta-proteinJ Biol Chem1993 2682295922962
Not in our library
205.
Gandy S Czernik AJ Greengard P Phosphorylation of Alzheimer disease amyloid precursor peptide by protein kinase C and Ca2+/calmodulin-dependent protein kinase IIProc Natl Acad Sci USA1988 8562186221
Not in our library10.1073/pnas.85.16.6218
206.
Xu H Greengard P Gandy S Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor proteinJ Biol Chem1995 2702324323245
Not in our library10.1074/jbc.270.40.23243
207.
Xu H Sweeney D Greengard P Gandy S Metabolism of Alzheimer beta-amyloid precursor protein: regulation by protein kinase A in intact cells and in a cell-free systemProc Natl Acad Sci USA1996 9340814084
Not in our library10.1073/pnas.93.9.4081
208.
Driscoll I Resnick SM Testosterone and cognition in normal aging and Alzheimer's disease: an updateCurr Alzheimer Res2007 43345
Not in our library10.2174/156720507779939878
209.
Goodenough S Engert S Behl C Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathwayNeurosci Lett2000 2964952
Not in our library10.1016/s0304-3940(00)01622-0
210.
Testosterone reduces neuronal secretion of Alzheimer's β-amyloid peptides · 2000
Not checked
211.
McAllister C Long J Bowers A Walker A Cao P Honda S Harada N Staufenbiel M Shen Y Li R Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairmentJ Neurosci2010 3073267334
Not in our library10.1523/jneurosci.1180-10.2010

Cited by papers we hold 22

Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy · 2024
No notice
WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective · 2023
No notice
Microglia and Astrocytes in Alzheimer’s Disease: Significance and Summary of Recent Advances · 2023
No notice
ER stress and UPR in Alzheimer’s disease: mechanisms, pathogenesis, treatments · 2022
No notice
Defective Autophagy and Mitophagy in Aging and Alzheimer’s Disease · 2021
No notice
Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure · 2021
No notice
Lipopolysaccharide exposure during late embryogenesis triggers and drives Alzheimer‐like behavioral and neuropathological changes in CD‐1 mice · 2020
Not checked
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies · 2020
No notice
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease · 2020
No notice
Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress · 2020
No notice
ER-mitochondria contact sites in neurodegeneration: genetic screening approaches to investigate novel disease mechanisms · 2020
Corrected
The P2X7 Receptor: Central Hub of Brain Diseases · 2020
No notice
The Nervous System Relevance of the Calcium Sensing Receptor in Health and Disease · 2019
Not checked
Potential therapeutic roles of retinoids for prevention of neuroinflammation and neurodegeneration in Alzheimer’s disease · 2019
Not checked
Alzheimer’s disease: risk factors and potentially protective measures · 2019
No notice
Ketogenic Diet in Alzheimer’s Disease · 2019
No notice
Role of Copper in the Onset of Alzheimer’s Disease Compared to Other Metals · 2018
No notice
Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases · 2016
No notice
Trafficking regulation of proteins in Alzheimer’s disease · 2014
No notice
The Î³-secretase complex: from structure to function · 2014
No notice

and 2 more

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.